Metabolic defects underlying dyslipidemia in abdominal obesity

Similar documents
Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

The rapid increase in obesity prevalence is one of the

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

Pathophysiology of Lipid Disorders

3/20/2011. Body Mass Index (kg/[m 2 ]) Age at Issue (*BMI > 30, or ~ 30 lbs overweight for 5 4 woman) Mokdad A.H.

METABOLISM of ADIPOSE TISSUE

Zuhier Awan, MD, PhD, FRCPC

Obesity, Metabolic Syndrome, and Diabetes: Making the Connections

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

The Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

High density lipoprotein metabolism

Gene Polymorphisms and Carbohydrate Diets. James M. Ntambi Ph.D

Roadmap. Diabetes and the Metabolic Syndrome in the Asian Population. Asian. subgroups 8.9. in U.S. (% of total

Non alcoholic fatty liver disease and atherosclerosis Raul Santos, MD

The art of tracing dietary fat in humans. Leanne Hodson

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

The role of apolipoprotein D in lipid metabolism and metabolic syndrome

Metabolic Syndrome: An overview. Kevin Niswender MD, PhD Vanderbilt University School of Medicine

Bachelorarbeit Fructose and weight gain

Metabolic Syndrome in Asians

Supplementary Table 2. Plasma lipid profiles in wild type and mutant female mice submitted to a HFD for 12 weeks wt ERα -/- AF-1 0 AF-2 0

Acute suppression of VLDL 1 secretion rate by insulin is associated with hepatic fat content and insulin resistance

Responses of blood lipids to aerobic and resistance type of exercise

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

* Author to whom correspondence should be addressed; Tel.: ; Fax:

Diabetic dyslipidaemia: from basic research to clinical practice*

Establishment of Efficacy of Intervention in those with Metabolic Syndrome. Dr Wendy Russell - ILSI Europe Expert Group

Lipoproteins Metabolism

Chapter (5) Etiology of Low HDL- Cholesterol

Fast-food, Fatty liver, & Insulin Resistance. Giulio Marchesini Clinical Dietetics Alma Mater Studiorum University of Bologna

FoodGate: The break-in, cover-up, and aftermath. Robert H. Lustig, M.D., M.S.L. Cristin Kearns, D.D.S., M.B.A. Laura Schmidt, Ph.D., M.P.H., L.C.S.W.

Hmgcoar AGCTTGCCCGAATTGTATGTG TCTGTTGTAACCATGTGACTTC. Cyp7α GGGATTGCTGTGGTAGTGAGC GGTATGGAATCAACCCGTTGTC

Metabolism and Atherogenic Properties of LDL

Menopausal Status and Abdominal Obesity Are Significant Determinants of Hepatic Lipid Metabolism in Women

Effect of fructose overfeeding. hepatic de novo lipogenesis and insulin sensitivity in healthy males

Lipid/Lipoprotein Structure and Metabolism (Overview)

ANSC/NUTR 618 LIPIDS & LIPID METABOLISM Lipoprotein Metabolism

13/09/2012. Dietary fatty acids. Triglyceride. Phospholipids:

NAFLD AND TYPE 2 DIABETES

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA

"Fatty acid dysregulation in NAFLD" Studying the fasting to fed state transition. Outline

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Interactions of exercise and diet in health prevention

METABOLIC SYNDROME AND HCV: FROM HCV

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Cardiovascular Complications of Diabetes

Lipoprotein Particle Profile

Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk

Cholesterol metabolism. Function Biosynthesis Transport in the organism Hypercholesterolemia

HIV VPR alters fat metabolism. Dorothy E Lewis PhD/Ashok Balasubramanyam MD

Overproduction of Very Low Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome

HSN301 Diet and Disease Entire Note Summary

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

Association between skeletal muscle fat content and very-low density. lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

Plasma lipoproteins & atherosclerosis by. Prof.Dr. Maha M. Sallam

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Impact of Exercise on Patients with Diabetes Mellitus

Energy balance. Factors affecting energy input. Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain

N-3 Fatty Acids Non-HDL-Cand LDL-C Thomas Dayspring MD, FACP

Lipids digestion and absorption, Biochemistry II

Lipid Metabolism Prof. Dr. rer physiol. Dr.h.c. Ulrike Beisiegel

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

Unit IV Problem 3 Biochemistry: Cholesterol Metabolism and Lipoproteins

Metabolic syndrome. Metabolic syndrome and prediabetes appear to be the same disorder, just diagnosed by a different set of biomarkers.

We are being killed by fructose by Robert Harrison Black

The spectrum of nonalcoholic fatty liver disease (NAFLD)

Replacement Of Partially Hydrogenated Soybean Oil By Palm Oil In Margarine Without Unfavorable Effects On Serum Lipoproteins

Metabolic Syndrome.

Lipoprotein Pathophysiology. Lipoprotein Pathophysiology

NOTES. Developed by Fabio Comana, MA., MS., All rights Reserved Page 1

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

Niacin Metabolism: Effects on Cholesterol

ADVANCED CARDIOMETABOLIC SCREENING

Adipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University

3-Thia Fatty Acids A New Generation of Functional Lipids?

Treatment of Atherosclerosis in 2007

Fructose in diabetes: Friend or Foe. Kim Chong Hwa MD,PhD Sejong general hospital, Division of Endocrinology & Metabolism

Prof. John Chapman, MD, PhD, DSc

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Fat Metabolism, Insulin and MTHFR

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

Changes in Cardiotrophin-1 and Fibroblast Growth Factor-21 with Weight Loss. Robert Lawrence Bowers

Internal and Emergency Medicine Official Journal of the Italian Society of Internal Medicine. ISSN Volume 8 Number 3

Tesamorelin Clinical Data Overview Jean-Claude Mamputu, PhD Senior Medical Advisor, Theratechnologies

CHAPTER FORTY FIVE ENDOGENOUS LIPID TRANSPORT PATHWAY: VLDL AND IDL

Energy balance. Factors affecting energy input. Energy input vs. Energy output Balance Negative: weight loss Positive: weight gain

The Metabolic Syndrome Prof. Jean-Pierre Després

Metabolic syn and CVD. Dr : dehestani Imam reza hospital

Lipids Carbohydrate Protein. Fatty Acids Glycerol. Mono/di-saccarides. Aminoacids. Fat Liver Muscle. Triglycerides Glycogen Protein

Widespread concern about the role of SFA in heart disease: Is it justified?

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015


Transcription:

Metabolic defects underlying dyslipidemia in abdominal obesity Professor Marja-Riitta Taskinen Department of Medicine, Division of Cardiology Helsinki University Hospital, Finland Disclosures: Honorariums/ Consultant to MSD, Novartis, Kowa, Sanofi-Aventis

What is ectopic fat accumulation? Caloric Intake and/ or Energy Expenditure Positive Energy Balance Lipid overflow into liver, pancreas, muscle and heart FFA Inflamed adipose tissue Imbalance between loading and export of lipids results in ectopic fat accumulation at organs

The fatty liver produces most CVD risk factors uc l G e s o V L D L L D H ALT, AST Genetic Predisposition Caloric excess Fat in the diet? Fructose Sucrose The Fatty Liver ; Overproduction of Cardiometabolic Risk Factors Fibrinogen Angiotensinogen CRP, SAA TNF-а, IL-6 FVII, PAI-1

Is liver fat the culprit of dyslipidemia? Hepatic steatosis(nafld) is linked to insulin resistance in the liver Hepatic steatosis associates with features of the atherogenic lipid triad Hepatic steatosis associates with intraabdominal obesity

Regulation of lipid metabolism in the liver FFA flux Dietary fatty acids DNL Fatty acid oxidation VLDL assembly VLDL secretion

Determination of liver fat content using MR spectroscopy water peak Liver fat 6 % Liver fat 23 % triglyceride peak Ryysy L et al. Diabetes, 2000

VLDL1 TG production Relationship between VLDL1 production rate and plasma VLDL1 TG pools mg/kg/day 600 r=0.62 p<0.001 400 200 0 0 10 20 30 40 50 60 VLDL1 TG pool, mg/kg VLDL1 TG production rate is the predictor for VLDL1 TG pool size Adiels M et al. ATVB 2005;25:1697-703

VLDL1 TG production is linked with detrimental changes of LDL size and HDL cholesterol LDL size vs VLDL1 TG production mg/kg/day HDL Chol vs VLDL1 TG production mg/kg/day 600 r=-0.56 p< 0.005 500 600 500 400 400 300 300 200 200 100 100 0 22 23 24 25 26 27 LDL size, nm 28 29 30 r=-0.64 p< 0.001 0 0.7 0.9 1.1 1.3 1.5 1.7 HDL Cholesterol, mmol/l Adiels M et al. Diabetologia 2006;49:755-65

The relationship between VLDL1 production and liver fat assessed using proton spectroscopy TG VLDL1 production mg/kg/day 600 400 200 r=0.58 p<0.01 0 0 5 10 15 Liver fat 20 25 % Liver fat content is the driving force for VLDL TG overproduction Adiels M et al. Diabetologia 2006;49:755-765

Defective regulation of VLDL metabolism by insulin in Type 2 diabetes patients Oxidation Denovo lipogenesis mg/day FFA 1000 FA Remnants Chol ester Degradation TG VLDL1 apo B production 500 0 MTP VLDL2 apob IDL LDL LPL HL IDL HL LDL Small dense LDL LPL -51% Controls Type 2 VLDL1 LPL VLDL2 Insulin fails to suppress VLDL1 apo B production Accumulation of VLDL1 particles

Characteristics of the subjects Low liver fat (n=10) BMI, kg/m2 Subcutaneous fat, cm2 Intra-abdominal fat, cm2 Liver fat, % M-value, mg kg-1 min-1 F-triglycerides, mmol/l HDL-chol, mmol/l LDL size, nm 26.0±2.9 2150±731 1600±878 2.1±1.5 6.4±1.8 1.4±0.5 1.4±0.2 26.6±0.8 High liver fat (n=10) 28.4±3.6 2420±522 2480±861* 11.2±4.7*** 4.0±2.1* 2.0±0.8 1.1±0.3** 25.3±1.1** Adiels M et al. Diabetologia 2007;50:2356-2365

High liver fat: lack of VLDL1 suppression in response to insulin Low liver fat <5.5% High liver fat >5.5% % of total VLDL at baseline VLDL1 TG production rate 100 75 Δ 61% p<0.01 50 25 0 0 100 300 500 Time (min) Adiels M et al. Diabetologia 2007;50:2356-2365

Normal production and regulation of VLDL1 particles in normal healthy subjects Low Liver Fat Insulin TG apob VLDL1 VLDL2 VLDL2 Adiels M et al. Diabetologia 2007;50:2356-2365

Overproduction and dysregulation of VLDL1 particles in Type 2 diabetes High Liver Fat Insulin TG apob VLDL1 VLDL2 VLDL2 High liver fat is linked with hepatic insulin resistance and overproduction of large VLDL particles Adiels M et al. Diabetologia 2007;50:2356-2365

Sources of fatty acids for liver and VLDL-TG FFA POOL 2 CM 2 TG DNL GLUCOSE 3 1 FA STORAGE? β-ox 4 LIVER TG ApoB 5 VLDL TG INSULIN Adiels M et al. ATVB, 2008;28;1225-1236

Whole-body palmitate rate of appearance in obese subjects without and with NAFLD Palmitate RA (µmol/min) (n=14 in both groups) 160 NAFLD * 120 Normal IHTG 80 40 0 Liver fat % BMI (kg/m2) 3.4 ± 0.4 35.3 ± 1.3 22.7 ± 2.0 36.8 ± 1.2 The rate of the release of fatty acids from AT is increased in obese subjects with NAFLD Fabbrini E et al. Gastroenterology 2008;134:424-431

VLDL-TG secretion rate is increased in obese subjects with NAFLD Non-systemic fatty acids 30 * Systemic plasma FFA (µmol/min) 25 20 15 10 5 0 Liver fat % BMI (kg/m2) * 3.4 ± 0.4 35.3 ± 1.3 22.7 ± 2.0 36.8 ± 1.2 Fatty acids derived from nonsystematic sources are the major factors responsible for the increase in VLDL-TG secretion Fabbrini E et al. Gastroenterology 2008;134:424-431

Sources of fatty acids for liver fat and VLDL-Triglycerides Increased rate of FFA flux from AT results in increased rate of hepatic FFA uptake Intrahepatic DNL is enhanced in subjects with NAFLD The production and secretion of large VLDL particles correlates with liver fat content Basal hepatic lipid oxidation seems to be unaltered in subjects with NAFLD Overproduction of VLDL particles is NOT able to adequately compensate for increase of hepatic TG production liver fat accumulation

Regulation of DNL by SREBP1-C, ChREBP and LXRs in liver Insulin signaling pathway Glucose signaling pathway LXR LXR? SREBP-1 + + + + + + +? ChREBP GK L-PK ACC FAS ELOVL-6 SCD-1 GPAT DGAT + + + +?? TG Postic C and Girard J. J Clin Invest 2008;118:829-838

Imbalance of liporegulation; the culprit of fatty liver and dyslipidemia Insulin resistance/ Hyperinsulinemia Inflamed adipose tissue FFA flux Excess dietary fat De Novo lipogenesis ECS dysregulation Lipid oxidation VLDL Atherogenic dyslipidemia

Why do not all people with a big waist have dyslipidemia? Elevated VLDL1 concentrations Insulin resistance Normal lipid profile Visceral obesity Insulin resistance Visceral obesity Low HDL The atherogenic triad Small, dense LDL particles

My warmest thanks for my collaborators Current players Gothenburg The ladies of the lab Imaging Team Anne Hiukka Aino Soro-Paavonen Sanni Söderlund Jukka Westerbacka Hannele Yki-Järvinen Hannele Hilden Virve Naatti Helinä Perttunen-Nio Martin Adiels Jan Boren Sven-Olof Olofsson Nina Lundbom Jesper Lundbom Antti Hakkarainen